To detect hEMAP-II by direct ELISA (using 100 μ,L/well antibody solution) a concentration of at least 0.5 μ,g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hEMAP-II.
Sandwich: To detect hEMAP-II by sandwich ELISA (using 100 μ,L/well antibody solution) a concentration of 0.5 - 2.0 μ,g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with our Biotinylated Anti-Human EMAP-II (XP-5122Bt) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hEMAP-II.
Western Blot:
To detect hEMAP-II by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μ,g/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant hEMAP-II is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Restrictions
For Research Use only
Format
Lyophilized
Stock
-20 °C
Stockage commentaire
EMAP-II antibody is stable for at least 2 years from date of receipt at -20°C. The reconstituted antibody is stable for at least two weeks at 2-8°C. Frozen aliquots are stable for at least 6 months when stored at -20°C. Avoid repeated freeze-thaw cycles.
Antigène
AIMP1
(Aminoacyl tRNA Synthetase Complex-Interacting Multifunctional Protein 1 (AIMP1))
EMAP II is a cytokine that is specifically induced by apoptosis. The release of this cytokine renders the tumor associated vasculature sensitive to tumor necrosis factor. Its precursor is identical to the p43 subunit, which is associated with the multi tRNA synthetase complex. Therefore, proEMAP II may function in binding RNA as part of the tRNA synthetase complex in normal cells and in stimulating inflammatory responses after proteolytic cleavage in tumor cells. EMAP II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues.